Abstract
A key step in the processing of the integral membrane protein APP, or Amyloid Precursor Protein is through the proteolytic cleavage by the enzyme β-Secretase (BACE). The proteolysis of APP by BACE, followed by subsequent C-terminal cleavage(s) by γ-secretase, results in the formation of the amyloidβ(Aβ ) peptide. The principal component of the neuritic plaque found in the brains of Alzheimers Disease (AD) patients is Aβ which is a neurotoxic and highly aggregatory peptide segment of APP. The amyloid hypothesis holds that the neuronal dysfunction and clinical manifestation of AD is a consequence of the long term deposition and accumulation of 40-42 amino-acid long A β peptides, and that this process leads to the onset and progression of AD. Due to the apparent causal relationship between Aβ and AD, the so-called "secretases" that produce Aβ have been targeted for development of inhibitors that might serve as therapeutic agents for treatment of this dreaded, and ever more prevalent disease. Herein will be discussed our current understanding of BACE, its role in the formation of neuritic plaques and the known inhibitors of the enzyme.
Keywords: amyloidogenic pathway, Alzheimer, ’, s disease, Hydroxyethylene inhibitors, APP processing, hydroxymethylcarbonyl (HMC)
Current Topics in Medicinal Chemistry
Title: Human β-secretase (BACE) and BACE Inhibitors: Progress Report
Volume: 6 Issue: 6
Author(s): Varghese John
Affiliation:
Keywords: amyloidogenic pathway, Alzheimer, ’, s disease, Hydroxyethylene inhibitors, APP processing, hydroxymethylcarbonyl (HMC)
Abstract: A key step in the processing of the integral membrane protein APP, or Amyloid Precursor Protein is through the proteolytic cleavage by the enzyme β-Secretase (BACE). The proteolysis of APP by BACE, followed by subsequent C-terminal cleavage(s) by γ-secretase, results in the formation of the amyloidβ(Aβ ) peptide. The principal component of the neuritic plaque found in the brains of Alzheimers Disease (AD) patients is Aβ which is a neurotoxic and highly aggregatory peptide segment of APP. The amyloid hypothesis holds that the neuronal dysfunction and clinical manifestation of AD is a consequence of the long term deposition and accumulation of 40-42 amino-acid long A β peptides, and that this process leads to the onset and progression of AD. Due to the apparent causal relationship between Aβ and AD, the so-called "secretases" that produce Aβ have been targeted for development of inhibitors that might serve as therapeutic agents for treatment of this dreaded, and ever more prevalent disease. Herein will be discussed our current understanding of BACE, its role in the formation of neuritic plaques and the known inhibitors of the enzyme.
Export Options
About this article
Cite this article as:
John Varghese, Human β-secretase (BACE) and BACE Inhibitors: Progress Report, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743084
DOI https://dx.doi.org/10.2174/156802606776743084 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiopharmaceuticals Regulations: Current Scenario and the Way Forward
Applied Clinical Research, Clinical Trials and Regulatory Affairs Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Physicochemical Assessment of Branded and Generic Linezolid Injection from Different Pharmaceutical Manufacturers
Current Pharmaceutical Analysis Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design A RasMol study of the Mechanism of Inhibition of Cysteine Endopeptidase Enzyme Papain
Current Proteomics WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
Current Cancer Drug Targets Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Meet Our Associate Editor
Current Alzheimer Research Drug Abuse, Brain Calcification and Glutamate-Induced Neurodegeneration
Current Drug Abuse Reviews Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF) and its Possible Role in Tumour Progression During Malignant Transformation of Atrophic Epithelium in Oral Submucous Fibrosis
Current Angiogenesis (Discontinued) Adult Stem Cells and Mammalian Epimorphic Regeneration-Insights from Studying Annual Renewal of Deer Antlers
Current Stem Cell Research & Therapy Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics The Use of Cell Products for Treatment of Autoimmune Neuroinflammatory Diseases
Current Medicinal Chemistry Phosphorylation-Specific Prolyl Isomerase Pin1 as a new Diagnostic and Therapeutic Target for Cancer
Current Cancer Drug Targets Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Pharmacotherapy for Hoarding Disorder: How did the Picture Change since its Excision from OCD?
Current Neuropharmacology